EAM
TAK icon

Eagle Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Eagle Asset Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-34,664
Closed -$495K – 612
2023
Q4 		$495K Sell
34,664
-1,549
-4% -$22K ﹤0.01% 512
2023
Q3 		$560K Sell
36,213
-1,039
-3% -$16.1K ﹤0.01% 493
2023
Q2 		$585K Sell
37,252
-1,382
-4% -$22.6K ﹤0.01% 484
2023
Q1 		$636K Buy
38,634
+1,639
+4% +$26.1K ﹤0.01% 490
2022
Q4 		$583K Buy
+36,995
New +$517K ﹤0.01% 495

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eagle Asset Management's TAK Position: Q1 2024 in Review

Eagle Asset Management sold out of Takeda Pharmaceutical (TAK) in Q1 2024, closing a stake of 34,664 shares — an estimated $495K sold.

Eagle Asset Management first reported a position in TAK in Q4 2022 and held it in 5 quarters. The position peaked at $636K in Q1 2023. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2024.

  • Eagle Asset Management reported no remaining Takeda Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Eagle Asset Management sold 34,664 Takeda Pharmaceutical shares in Q1 2024, an estimated $495K.
  • Eagle Asset Management first reported a position in Takeda Pharmaceutical in Q4 2022 and held it in 5 quarters.
  • Eagle Asset Management's Takeda Pharmaceutical position peaked at $636K in Q1 2023.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.